Cargando…

Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus

OBJECTIVES: Patients with systemic lupus erythematosus (SLE) are usually treated with glucocorticosteroids even during periods of clinically quiescent disease. A recent study showed that abrupt glucocorticoid withdrawal was associated with an increased likelihood of flare in the next 12 months. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tselios, Konstantinos, Gladman, Dafna D., Su, Jiandong, Urowitz, Murray B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363847/ https://www.ncbi.nlm.nih.gov/pubmed/34245233 http://dx.doi.org/10.1002/acr2.11267

Ejemplares similares

Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
por: Tselios, Konstantinos, et al.
Publicado: (2016)

Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus
por: Medina-Rosas, Jorge, et al.
Publicado: (2015)

Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease
por: Al Rayes, Hanan, et al.
Publicado: (2017)

Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus
por: Sivakumaran, Jagan, et al.
Publicado: (2021)

Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study
por: Nikpour, Mandana, et al.
Publicado: (2010)

Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study
por: Nikpour, Mandana, et al.
Publicado: (2011)

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
por: Mai, Lloyd, et al.
Publicado: (2021)

Development validation and reliability of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50
por: Touma, Z, et al.
Publicado: (2012)

Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus
por: Souliotis, Vassilis L., et al.
Publicado: (2016)

Effective and Safe Use of Glucocorticosteroids for Rescue of Late ARDS
por: Diana, Paolo, et al.
Publicado: (2017)

The Role of Anti-Phosphatidylserine/Prothrombin Antibodies in Thrombotic Manifestations of Systemic Lupus Erythematosus Patients
por: Tselios, Konstantinos, et al.
Publicado: (2013)

Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus
por: Capone, Gabrielle, et al.
Publicado: (2021)

Nonlymphoma hematological malignancies in systemic lupus erythematosus
por: Lu, M, et al.
Publicado: (2012)

Lung cancer in systemic lupus erythematosus
por: Kale, M, et al.
Publicado: (2012)

Quiescent Systemic Lupus Erythematosus Manifesting with Thrombotic Thrombocytopenic Purpura and Acute Renal Failure: A Case Report and Short Literature Review
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2021)

Glucocorticoid Withdrawal Symptoms and Quality of Life in Patients with Systemic Lupus Erythematosus
por: Karoonkatima, Matee, et al.
Publicado: (2023)

Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
por: Urowitz, Murray B, et al.
Publicado: (2015)

Influenza A/H1N1 septic shock in a patient with systemic lupus erythematosus. A case report
por: Tselios, Konstantinos, et al.
Publicado: (2011)

Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study
por: Huang, Hong, et al.
Publicado: (2021)

Glucocorticosteroid in Treatment of Severe Pneumonia
por: Ariani, Felinda, et al.
Publicado: (2013)

Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis
por: Whittall-Garcia, Laura, et al.
Publicado: (2022)

Class IV Lupus Nephritis in the Setting of Serologically Quiescent Disease and Normal Urine Sediment in a Patient with Late-Onset Systemic Lupus Erythematosus
por: Nnodum, Benedicta, et al.
Publicado: (2019)

Severe Pericardial Effusion Due to Autoimmune Hypothyroidism With Levothyroxine Withdrawal and Systemic Lupus Erythematosus
por: Israel, Sylvernon, et al.
Publicado: (2022)

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
por: Bruce, Ian N, et al.
Publicado: (2015)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

THE EFFECT OF GLUCOCORTICOSTEROIDS ON THE KINETICS OF MONONUCLEAR PHAGOCYTES
por: Thompson, Jan, et al.
Publicado: (1970)

Effect of glucocorticosteroids on epidermal Langerhans cells
Publicado: (1982)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials
por: Furie, Richard, et al.
Publicado: (2014)

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
por: Parker, Ben, et al.
Publicado: (2013)

Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort
por: Urowitz, M B, et al.
Publicado: (2016)

Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study
por: Conti, Fabrizio, et al.
Publicado: (2012)

Systemic Lupus Erythematosus and COVID-19
por: Pappa, Maria, et al.
Publicado: (2023)

Systemic Lupus Erythematosus and Pulmonary Hypertension
por: Parperis, Konstantinos, et al.
Publicado: (2023)

Testosterone Concentrations in Men on Chronic Glucocorticosteroid Therapy
por: Fitzgerald, Rebecca C, et al.
Publicado: (1997)

Glucocorticosteroids and the Risk of NAFLD in Inflammatory Bowel Disease
por: Jarmakiewicz-Czaja, Sara, et al.
Publicado: (2022)

Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria
por: van Vollenhoven, Ronald, et al.
Publicado: (2022)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

The Gradual Reduction vs. the Hyoscine or Quick Withdrawal Method in the Treatment of the Morphine Habit
por: Ashworth, W. C.
Publicado: (1912)

Cancer risk factors in systemic lupus erythematosus: multivariate regression analysis in 16,409 patients
por: Bernatsky, Sasha, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9043cah19q2k06hbpe6kssk7sc